Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) – Pipeline Review, H1 2017’, provides in depth analysis on Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)Additionally, the report provides an overview of key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Gastrointestinal, Respiratory, Central Nervous System, Immunology, Musculoskeletal Disorders and Ophthalmology under development targeting Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)

The report reviews Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Asana BioSciences LLC

AstraZeneca Plc

Boehringer Ingelheim GmbH

Onconova Therapeutics Inc

Oribase Pharma

TopiVert Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Overview

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Companies Involved in Therapeutics Development

AbbVie Inc

Asana BioSciences LLC

AstraZeneca Plc

Boehringer Ingelheim GmbH

Onconova Therapeutics Inc

Oribase Pharma

TopiVert Ltd

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Drug Profiles

AD-80 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASN-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilorasertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JRP-890 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nintedanib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-150030 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OR-0512 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saracatinib difumarate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1288 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1630 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPX-0005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Dormant Products

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Discontinued Products

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Jun 05, 2017: Encouraging Phase II survival data for oral nintedanib in malignant pleural mesothelioma presented at ASCO 2017

May 24, 2017: IPF patients treated with OFEV (nintedanib) versus placebo were twice as likely to have improved or stable lung function

Apr 04, 2017: Onconova Therapeutics Announces Positive Preclinical Data on ON dual FLT3 and Src inhibitor 150030 at 2017 American Association of Cancer Research Annual Meeting

Mar 20, 2017: Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases

Dec 14, 2016: Nintedanib granted orphan drug designation for treatment of mesothelioma

Dec 07, 2016: Clinically meaningful data for oral nintedanib in mesothelioma presented at World Conference on Lung Cancer

Nov 28, 2016: TopiVert Receives IND Approval for TOP1630 in the Treatment of Dry Eye Syndrome

Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST

Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO

Oct 06, 2016: First Patients Dosed in Phase 2a Proof-of-Concept Study With Rectal Formulation of TopiVert TOP1288 in Moderate to Severe Ulcerative Colitis

Sep 09, 2016: Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Sep 07, 2016: New long-term data demonstrates continued safety and beneficial effect of OFEV (nintedanib) for patients with IPF

Jul 27, 2016: First Study Initiated to Evaluate the Effect of Ofev Treatment on Biomarkers that may Predict IPF Progression

Jun 30, 2016: INMARK now enrolling: first study to evaluate the effect of OFEV (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients

Jun 27, 2016: New analysis of INPULSIS trials demonstrates efficacy of OFEV (nintedanib) across a range of IPF patients using broader diagnostic criteria

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by AbbVie Inc, H1 2017

Pipeline by Asana BioSciences LLC, H1 2017

Pipeline by AstraZeneca Plc, H1 2017

Pipeline by Boehringer Ingelheim GmbH, H1 2017

Pipeline by Onconova Therapeutics Inc, H1 2017

Pipeline by Oribase Pharma, H1 2017

Pipeline by TopiVert Ltd, H1 2017

Dormant Products, H1 2017

Dormant Products, H1 2017 (Contd..1), H1 2017

Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports